Europe Cardiac Biomarkers Market Size & Outlook, 2026-2033
- Clinical Diagnostics
- Biomarkers
- cardiac biomarker market
- Biomarkers
Global Market
Related Markets
Ask Prism AI about the cardiac biomarker market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
Europe cardiac biomarkers market highlights
- The Europe cardiac biomarkers market generated a revenue of USD 4,921.8 million in 2025.
- The market is expected to grow at a CAGR of 10.6% from 2026 to 2033.
- In terms of segment, troponin was the largest revenue generating type in 2025.
- Troponin is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 4,921.8 million |
| Market revenue in 2033 | USD 10,956.4 million |
| Growth rate | 10.6% (CAGR from 2026 to 2033) |
| Largest segment | Troponin |
| Fastest growing segment | Troponin |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CK-MB, Myoglobin, Troponin, BNP and NT-proBNP |
| Key market players worldwide | Abbott Laboratories, QuidelOrtho Corp, Siemens Healthineers AG ADR, Roche Holding AG ADR, Danaher Corp, BioMerieux SA, Bio-Rad Laboratories Inc, Randox, Creative Diagnostics, Life Diagnostics |
Other key industry trends
- In terms of revenue, Europe region accounted for 23.6% of the global cardiac biomarkers market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 12,660.4 million by 2033.
Europe has reported CVDs as the leading cause of death among the European population as compared to other diseases. The risk burden of CHD and heart attack is the maximum in the European region.
One of the prime risk factors of heart diseases is high blood pressure, which is a high concern within Europe, as a result, the healthcare priority of the region centers on its diagnosis, treatment, and control. In an effort to cut down healthcare spending, healthcare regulatory bodies in the EU are increasingly focused toward curbing the economic burden stemming from the high incidence of CVDs.
Germany largely focuses on R&D and new product innovation in diagnostics. For instance, Roche invested 240 million Swiss in 2012 to set up the production of diagnostics in Germany. Healthcare spending in Germany, which is 11.3 % of the total GDP, is allocated for the development of the healthcare infrastructure. on
No credit card required*
Publish Date: Mar 16, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cardiac Biomarker Market
Cardiac Biomarker Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Siemens Healthineers AG ADR | View profile | 71,400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | www.siemens-healthineers.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| QuidelOrtho Corp | View profile | 7,100 | 9975 Summers Ridge Road, San Diego, CA, United States, 92121 | www.quidelortho.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Creative Diagnostics | View profile | 51-100 | New York, New York, United States, North America | www.creative-diagnostics.com |
| Randox | View profile | 1001-5000 | Crumlin, Antrim, United Kingdom, Europe | www.randox.com |
| Life Diagnostics | View profile | 1-10 | West Chester, Pennsylvania, United States, North America | lifediagnostics.com |
Europe cardiac biomarker market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cardiac Biomarkers Market Outlook will help companies and investors design strategic landscapes.
Troponin was the largest segment with a revenue share of 39.9% in 2025.
Horizon Databook has segmented the Europe cardiac biomarkers market based on ck-mb, myoglobin, troponin, bnp and nt-probnp covering the revenue growth of each sub-segment from 2021 to 2033.
Europe has reported CVDs as the leading cause of death among the European population as compared to other diseases. The risk burden of CHD and heart attack is the maximum in the European region.
One of the prime risk factors of heart diseases is high blood pressure, which is a high concern within Europe, as a result, the healthcare priority of the region centers on its diagnosis, treatment, and control. In an effort to cut down healthcare spending, healthcare regulatory bodies in the EU are increasingly focused toward curbing the economic burden stemming from the high incidence of CVDs.
Germany largely focuses on R&D and new product innovation in diagnostics. For instance, Roche invested 240 million Swiss in 2012 to set up the production of diagnostics in Germany. Healthcare spending in Germany, which is 11.3 % of the total GDP, is allocated for the development of the healthcare infrastructure. on
- Europe Cardiac Biomarkers Market Type Outlook (Revenue, USD Million , 2021-2033)
- Troponin
- CK-MB
- Myoglobin
- BNP and NT-proBNP
- Others
- Europe Cardiac Biomarkers Market Application Outlook (Revenue, USD Million , 2021-2033)
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
- Europe Cardiac Biomarkers Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Laboratory Testing
- Point of Care Testing
Reasons to subscribe to cardiac biomarker market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of cardiac biomarker market databook
- Our clientele includes a mix of cardiac biomarker market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe cardiac biomarker market, including forecasts for subscribers. This continent databook contains high-level insights into Europe cardiac biomarker market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Cardiac Biomarkers Market, 2021-2033 (US$M)
Europe cardiac biomarker market statistics, by type, 2021-2033 (US$M)
